Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series

Joh, Hee Jung; Jin, Sang Wook

doi:10.1007/s10384-019-00673-8

Cited by 9 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies in the literature reported adverse drug reactions similar to those in our study after BBFC. 7 , 15 , 16 , 17 , 18 , 19 , 20 Similar to our study, Lerner et al 7 , reported that the rate of ocular adverse effects was 11.9% in patients who received maximum medical therapy in the form of BBFC and a beta-blocker/PG analog. In the same study, ocular adverse effects were observed in 7.5% of the control group given the beta-blocker/PG analog combination alone.…”

Section: Discussionsupporting

confidence: 88%

“…Lerner et al 7 evaluated maximum medical therapy by investigating the additive efficacy of BBFC with travoprost/timolol fixed combination in 67 open-angle glaucoma and OHT patients and observed a statistically significant reduction in IOP in the group to which BBFC was added. Joh and Jin 18 divided patients who received maximum medical therapy into two groups, triple (dorzolamide-timolol combination + brimonidine + latanoprost) and double (tafluprost/timolol combination + BBFC) maximum therapy. No statistically significant difference was found between the double and triple maximum medical therapy groups in terms of IOP reduction rate, but the rate of ocular adverse effects such as conjunctival hyperemia and dry eye was significantly lower in the double maximum therapy group.…”

Section: Discussionmentioning

confidence: 99%

“…In previous studies in the literature, it is seen that the majority of patients treated with BBFC are diagnosed with POAG. 15 , 16 , 17 , 18 , 19 In contrast, our study included 48 patients with POAG (52.2%) and 35 patients with PEG (38.0%). BBFC provided effective IOP reduction in both POAG and PEG patients.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the Use of Brinzolamide-Brimonidine Fixed Combination in Maximum Medical Therapy

Tekeli¹,

Köse²

2022

tjo

View full text Add to dashboard Cite

Objectives: To investigate the intraocular pressure (IOP)-lowering efficacy, safety, and treatment tolerability of brinzolamide/ brimonidine fixed combination (BBFC) in maximum medical therapy. Materials and Methods: The medical records of 92 patients with glaucoma or ocular hypertension who had previously been treated with a different antiglaucomatous regimen and were switched to a treatment regimen that included BBFC were retrospectively analyzed. Patients were divided into 4 groups including 22, 20, 27, and 23 patients based on previous glaucoma treatment. All patients received maximum medical treatment regimen by adding a combination of beta blocker-prostaglandin analogue therapy along with BBFC. IOP values at baseline and month 1, month 3 and month 6 after starting BBFC and ocular adverse effects at follow-up visits were evaluated. Results: The mean age of all patients was 62.7±16.6 years (range: 18-90). Fifty-two patients (56.5%) were women and 40 (43.5%) were men. Forty-eight (52.2%) patients had primary open-angle glaucoma, 35 (38.0%) had pseudoexfoliation glaucoma, and 9 (9.8%) had ocular hypertension. The IOP of the all eyes was 21.1±4.8 mmHg (range: 17-25) before and 17.6±3.7 mmHg, 17.3±3.4, and 17.0±3.5 mmHg at month 1, 3, and 6 after the introduction of BBFC, respectively (p<0.001 for all time points compared to baseline). In all 4 groups, a significant decrease in IOP was observed at month 1, 3, and 6 follow-ups compared to baseline after the introduction of BBFC. The mean number of antiglaucoma drops was significantly reduced from 2.5±0.6 at baseline to 2 after BBFC (p<0.001). The most frequent ocular adverse event was ocular allergic reactions reported in 8 patients (8.7%), conjunctival hyperemia in 5 patients (5.4%), and ocular discomfort in 2 patients (2.5%). Conclusion: Maximum medical therapy with BBFC provides significant IOP reduction and antiglaucoma therapy simplification with a favorable safety profile in patients with glaucoma.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Use of Brinzolamide-Brimonidine Fixed Combination in Maximum Medical Therapy

Tekeli¹,

Köse²

2022

tjo

View full text Add to dashboard Cite

show abstract

“…Therefore, the IOP-lowering efficacies of TMT and DMT would be expected to be similar too and, in fact, our present results indicated equivalent IOP-lowering efficacies between TMT and DMT for the 60 POAG patients studied. Joh and Jin [19] analyzed two different combinations of maximum medical therapy for lowering the IOP administered in 82 POAG subjects. Specifically, they compared the IOP-lowering efficacies between a TMT group including patients who were treated with taf luprost, brimonidine, and a brinzolamide/timolol FDC and a DMT group including patients who were treated with a taf luprost/timolol FDC and a brinzolamide/brimonidine FDC, respectively.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma

Kim

Jeoung

et al. 2020

Korean J Ophthalmol

View full text Add to dashboard Cite

We sought to compare the efficacy as well as the safety of two maximum medical therapy combinations applied to lower the intraocular pressure (IOP) in different primary open-angle glaucoma (POAG) age groups. Methods: This was a retrospective, consecutive case series study that included 60 eyes of 60 subjects with POAG, specifically 20 subjects aged 40 to 54 years, 21 aged 55 to 69 years, and 19 aged 70 years or older. All had been treated for at least 12 months with triple maximum medical therapy (TMT; dorzolamide/timolol, brimonidine, and latanoprost) to lower their IOP, which subsequently was changed to double maximum medical therapy (DMT, fixed drug combinations of tafluprost/timolol and brinzolamide/brimonidine). The rate of IOP change and adverse drug reactions were compared amongst the three age groups. Results: The mean IOP change at three months after converting from TMT to DMT was-0.65 ± 1.42 mmHg (-3.84% ± 9.31%) among the overall study group, but this finding was not statistically significant (p = 0.108). In the 40 to 54 years and 55 to 69 years groups, the mean IOP change rates were +0.29 ± 0.96 mmHg (+2.40% ± 6.85%, p = 0.087) and-0.50 ± 0.99 mmHg (-3.05% ± 6.40%, p = 0.084) respectively. In the 70 years or older group, the mean IOP change, interestingly, was-1.80 ± 1.46 mmHg (-11.29% ± 9.31%, p < 0.001) and nine (47.4%) of the 19 subjects showed additional IOP reductions of 10% or more after converting from TMT to DMT. In all three age groups, the incidence rate of dry eye was significantly lower for DMT than for TMT (p = 0.031). Conclusions: In POAG patients, DMT was proven to be both effective and safe for lowering the IOP, especially in those 70 years or older group, when compared with the TMT protocol.

show abstract

“…Therefore, we expected the distribution of their use to change. The various fixed-combination eye drops have different efficacies in lowering intraocular pressure (IOP) and pose risks for different adverse reactions, 8–10 and ophthalmologists select such medications based on these factors. According to the 2020 survey, fixed-combination medications were used in 55.6% patients in the two-medications group, 79.8% in the three-medications group, 84.9% in the four-medications group, 91.3% in the five-medications group, and 94.1% in the six-medications group.…”

Section: Discussionmentioning

confidence: 99%

Frequency of Use of Fixed-Combination Eye Drops by Patients with Glaucoma at Multiple Private Practices in Japan

Inoue¹,

Komori²,

Kunimatsu-Sanuki³

et al. 2022

OPTH

View full text Add to dashboard Cite

Purpose To investigate the current use of fixed-combination eye drops by patients with glaucoma in Japan. Patients and Methods A total of 5303 outpatients (5303 eyes) with glaucoma or ocular hypertension were enrolled in the survey at 78 private practices from March 8 to 14, 2020. The medications they used were investigated. The use of fixed-combination medications was analyzed, stratified by the number of medications used. The results were compared to those of the survey performed in 2016 via χ 2 tests. Results Fixed-combination medications were used by 55.6%, 79.8%, 84.9%, 91.3%, and 94.1% of patients in the two-, three-, four-, five, and six-medications groups. The use of prostaglandin analog/β-blocker (PG/β), carbonic anhydrase inhibitor/β-blocker (CAI/β), and α-2-adrenergic agonist/β-blocker (α2/β) fixed-combination medications were 42.8%, 12.0%, and 0.8% in the two-medications group; 36.2%, 41.6%, and 2.0% in the three-medications group; and 23.5%, 60.1%, and 1.3% in the four-medications group, respectively. The most commonly used fixed-combination medications were PG/β in the two-medications group and CAI/β in the groups using three or more medications. Compared to those in the survey performed in 2016, there were increases (both P < 0.0001) in the use of PG/β fixed-combination medication in the two- (28.7% to 42.8%) and three-medications (21.7% to 36.2%) groups, and none in the use of CAI/β fixed-combination medication. There was little use of α2/β fixed-combination medication, probably because it was launched only three months before the survey. Conclusion The proportion of fixed-combination medications increased as the number of medications per patient increased.

show abstract

Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series

Cited by 9 publications

References 17 publications

Evaluation of the Use of Brinzolamide-Brimonidine Fixed Combination in Maximum Medical Therapy

Evaluation of the Use of Brinzolamide-Brimonidine Fixed Combination in Maximum Medical Therapy

Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma

Frequency of Use of Fixed-Combination Eye Drops by Patients with Glaucoma at Multiple Private Practices in Japan

Contact Info

Product

Resources

About